Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 1, 2011, Pages

  Yuan, Yang ^a,c   Zhao, Lei ^b,c   Chen, Yaxi ^b   Moorhead, John F ^c   Varghese, Zac ^c   Powis, Stephen H ^c   Minogue, Shane ^c   Sun, Zilin ^a   Ruan, Xiong Z ^b,c  

^a SOUTHEAST UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetic nephropathy; LDL receptor; SREBP cleavageactivating protein

Indexed keywords

3 HYDROXY 3 METHYLCLUTARYL COENZYME A REDUCTASE; ADVANCED GLYCATION END PRODUCT; BINDING PROTEIN; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; N EPSILON (CARBOXYMETHYL)LYSINE; OXIDOREDUCTASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN CLEAVAGE ACTIVATING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENDOPLASMIC RETICULUM; GLYCOSYLATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; MESANGIAL FOAM CELL; MESANGIUM CELL; PRIORITY JOURNAL;

EID: 79960053947     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00646.2010     Document Type: Article

References (37)

1. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998.
2. Brown MS, Goldstein JL. Atherosclerosis Scavenging for receptors. Nature 343: 508-509, 1990.
3. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340, 1997.
4. Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, Schlondorff D. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 39: 858-866, 1991.
5. Dunphy WG, Brands R, Rothman JE. Attachment of terminal Nacetylglucosamine to asparagine-linked oligosaccharides occurs in central cisternae of the Golgi stack. Cell 40: 463-472, 1985.
6. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993.
7. Giansanti R, Rabini RA, Romagnoli F, Fumelli D, Sorichetti P, Boemi M, Fumelli P. Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors: a study on a middle-aged and elderly population. Arch Gerontol Geriatr 29: 175-182, 1999.
8. Goldstein JL, Basu SK, Brunschede GY, Brown MS. Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell 7: 85-95, 1976.
9. Goldstein JL, Bose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 124: 35-46, 2006.
10. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26: 152-161, 1995.
11. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Diabetes, hemoglobin A1c, cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis 36: 272-281, 2000.
12. Hu B, Li D, Sawamura T, Mehta JL. Oxidized LDL through LOX-1 modulates LDL-receptor expression in human coronary artery endothelial cells. Biochem Biophys Res Commun 307: 1008-1012. 2003.
13. Kaushal GP, Elbein AD. Glycosidase inhibitors in study of glycoconjugates. Methods Enzymol 230: 316-329, 1994.
14. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl 75: S27-S31, 2000.
15. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54: 631-664, 1985.
16. Kramer-Guth A, Quaschning T, Pavenstadt H, Galle J, Nauck M, Baumstark MW, Schollmeyer P, Marz W, Wanner C. Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells. Nephrol Dial Transplant 12: 1336-1343, 1997.
17. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63: 601-637, 1994.
18. Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 36: 67-75, 1991.
19. Li YT. Studies on the glycosidases in jack bean meal. I. Isolation and properties of alpha-mannosidase. J Biol Chem 242: 5474-5480, 1967.
20. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37: 550-557, 1988.
21. Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Antiatherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 292: H2721-H2728, 2007.
22. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y. Serum levels of non-carboxymethyllysine advanced glycation end products are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complications 17: 16-21, 2003.
23. Morbois-Trabut L, Chabrolle C, Garrigue MA, Lasfargues G, Lecomte P. Apolipoprotein E genotype and plasma lipid levels in Caucasian diabetic patients. Diabetes Metab 32: 270-275, 2006.
24. Mulec H, Johnson SA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 335: 1537-1538, 1990.
25. Nerlich AG, Schleicher ED. N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 144: 41-47, 1999.
26. Nohturfft A, Bose-Boyd RA, Scheek S, Goldstein JL, Brown MS. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci USA 96: 11235-11240, 1999.
27. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1betainduced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14: 593-600, 2003.
28. Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH, Varghese Z. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol 26: 1150-1155, 2006.
29. Ruan XZ, Varghese Z, Moorhead JF. Inflammation modifies lipidmediated renal injury. Nephrol Dial Transplant 18: 27-32, 2003.
30. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5: 713-721, 2009.
31. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int 56: 440-451, 1999.
32. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int 60: 1716-1725, 2001.
33. Velasco A, Hendricks L, Moremen KW, Tulsiani DR, Touster O, Farquhar MG. Cell type-dependent variations in the subcellular distribution of alpha-mannosidase I and II. J Cell Biol 122: 39-51, 1993.
34. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 251: 87-101, 2002.
35. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, Levi M. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54: 2328-2335, 2005.
36. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atheroscler Suppl 6: 11-14, 2005.
37. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 8: 952-959, 2007.